by Cherry Salazar | Sep 22, 2025
Moderna, which led the biotechnology sector’s pandemic-driven surge, struggles to keep pace with the market. Moderna, Inc.’s windfall during the pandemic has now become its headwind. Once propelled to record highs by its breakthrough messenger RNA technology, the...
by Laura Turbay | Nov 13, 2024
The race to supply weight-loss drugs to nearly half of Americans that classify as obese, is on. Eli Lilly’s stock boomed after they released their blockbuster weight loss drug Zepbound last year, consecrating the Indiana-based drugmaker as one of the top...
by Laura Turbay | Sep 23, 2024
Small-cap biotech stocks plundered after a 2021 wild-run, but investors are hopeful that interest rate cuts and positive test results in oncology and autoimmune treatments will be the right prescription for the biopharma market. That would be welcome news for...
by Joseph V. Lingad | Dec 1, 2023
UnitedHealth Group is snapping up home-based care operators on a bet that as more Americans get older and sicker, they will want health services under their own roof. The insurance giant began vying to be the nation’s biggest home health provider in early 2021,...
by Joseph Lingad | Oct 21, 2023
UnitedHealth’s third-quarter earnings were driven by the strong top and bottom lines, quelling investors’ concerns about increasing medical services and costs among seniors. The stock gained 1.2% to $539.40 while the S&P 500 fell by 0.5% at the end of...
by Cailley LaPara | Sep 20, 2022
The economy may be ailing but dominant healthcare stocks have so far resisted infection, and look poised to continue thriving. Pharmacy retailer and insurer CVS (CVS) closed Friday at $102 per share, just about where it began the year. Leading drug manufacturer Eli...
